Crops tailor-made using new gene-splicing techniques should face fewer regulations than genetically modified organisms, EU negotiators agreed Thursday.  Critics are calling it a GMO rebrand; proponents say they are bringing science back in style. The late-night negotiations — dragged across the finish line with the help of the European Parliament’s far right — capped years of haggling over how to ease the path for a new generation of gene-editing technologies developed since 2001, when the EU’s notoriously strict regulations on GMOs were adopted. The deal’s backers tout NGT’s potential to breed climate-resilient plants that need less space and fertilizers to grow, and they argue the EU is already behind global competitors using the technology. But critics fear the EU is opening the door to GMOs and giving too much power to major seed corporations.   The agreement opens the door to “unlabelled — yet patented — GM crops and foods, boosting corporate market power while undermining the rights of farmers and consumers,” warned Franziska Achterberg of Save Our Seeds, an NGO opposing GMOs, calling the deal a “complete sell-out.” INNOVATION VS. CAPITULATION European lawmakers, however, were responding to fears that outdated GMO rules were holding back progress on more recent genomic tweaks with a lighter touch — and throttling innovations worth trillions of euros.  Currently, most plants edited using new precision breeding technology — which can involve reordering their DNA, or inserting genes from the same plant or species — are covered by the same strict rules governing GMOs that contain foreign DNA.  The deal struck by the EU’s co-legislators creates two classes for these more recent techniques. “NGT1” crops — plants that have only been modified using new tech to a limited extent and are thus considered equivalent to naturally occurring strains — would be eligible for less stringent regulations. In contrast, “NGT2” plants, which have had more genetic changes and traditional GMOs will continue to face the same rules that have been in place for over 20 years.  Speaking before the final round of negotiations, Danish Agriculture Minister Jacob Jensen argued that the bloc needs to have NGTs in its toolbox if it wants to compete with China and the U.S., which are already making use of the new tech.  The deal “is about giving European farmers a fair chance to keep up” echoed center-right MEP Jessica Polfjärd, the lead negotiator on the Parliament’s side of the deal. She added that the technology will allow for the bloc to “produce more yield on less land, reduce the use of pesticides, and plant crops that can resist climate change.” Polfjärd had struggled to keep MEPs on the same page even as the bill advanced into interinstitutional negotiations. Persistent objections from left-wing lawmakers, including a key Socialist, forced her to embrace support of lawmakers from the far-right Patriots for Europe, breaking the cordon sanitaire.  Martin Häusling, the Green parliamentary negotiator, called the result miserable, saying it gives a “carte blanche for the use of new genetic engineering in plants” that threatens GMO-free agriculture.  DAVID AND GOLIATH In a hard-won victory for industry, the final legislation allows for NGT crops to be patented.  For Matthias Berninger, executive vice president at the global biotech giant Bayer, it’s just good business. “When we talk about startup culture in Europe … we also need to provide reasonable intellectual property protections,” he said in an interview. Yet safeguards meant to prevent patent-holders from accumulating too much market power don’t go far enough for Arche Noah. The NGO advocating for seed diversity in Europe, warned of a “slow-motion collapse of independent breeding, seed-diversity and farmer autonomy” if the deal makes it to law as is. They have MEP Christophe Clergeau, the Parliament’s Social-Democrat negotiator who led the last-ditch resistance.  In an interview on Thursday morning, he gave it five to 10 years before small breeders have disappeared from the bloc and farmers are “totally dependent” on the likes of Bayer and other huge companies. (Berninger said Bayer doesn’t want to inhibit small breeders by enforcing patents on them.) The deal now needs to be endorsed by the Parliament and the Council of the EU before the new rules are adopted. At the end of the day, it’s up to consumers to pass judgment, DG SANTE’s food safety and innovation chief Klaus Berend said Thursday, appearing at the POLITICO Sustainable Future Summit directly before the late-night negotiations began.  “We know that in Europe, the general attitude toward genetically modified organisms and anything around it is rather negative,” he cautioned. The key question for new genomic techniques is “how will they be accepted by consumers?” Their acceptance, Berend added, “is not a given.” Rebecca Holland contributed to this report.

Today, as the world reaches a critical juncture in the fight against HIV/AIDS, tuberculosis (TB) and malaria, the EU must choose: match scientific breakthroughs with political will and investment or retreat, putting two decades of hard-won progress at risk. Having saved over 70 million lives, the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) has proven what smart, sustained investment can achieve.  But the impact of its work — the lives protected, the life expectancy prolonged, the systems strengthened, the innovations deployed — is now under threat due to declining international funding.  > The real question is no longer whether the EU can afford to invest in the > Global Fund, but whether it can afford to let these hard-won gains unravel. The real question is no longer whether the EU can afford to invest in the Global Fund, but whether it can afford to let these hard-won gains unravel. Declining international funding, climate change, conflict and drug resistance are reversing decades of progress. HIV prevention is hampered by rising criminalization and attacks on key populations, with 1.3 million new infections in 2024 — far above targets. TB remains the deadliest infectious disease, worsened by spreading multidrug resistance, even in Europe. Malaria faces growing resistance to insecticides and drugs, as well as the impacts of extreme weather. Without urgent action and sustained investment, these threats could result in a dangerous resurgence of all three diseases. The stakes could not be higher  The Global Fund’s latest results reveal extraordinary progress. In 2024 alone: * 25.6 million people received lifesaving antiretroviral therapy, yet 630,000 still died of AIDS-related causes; * 7.4 million people were treated for TB, with innovations like AI-powered diagnostics reaching frontline workers in Ukraine; and * malaria deaths, primarily among African children under five, have been halved over two decades, with 2.2 billion mosquito nets distributed and ten countries eliminating malaria since 2020. Yet one child still dies every minute from this treatable disease.  What makes this moment unprecedented is not just the scale of the challenge, but the scale of the opportunity. Thanks to extraordinary scientific breakthroughs, we now have the tools to turn the tide:  * lenacapavir, a long-acting antiretroviral, offers new hope for the possibility of HIV-free generations; * dual active ingredient mosquito nets combine physical protection with intelligent vector control, transforming malaria prevention; and  * AI-driven TB screening and diagnostics are revolutionizing early detection and treatment, even in the most fragile settings. Some of these breakthroughs reflect Europe’s continued research and development and the private sector’s leadership in global health. BASF’s dual-active-ingredient mosquito nets, recently distributed by the millions in Nigeria, are redefining malaria prevention by combining physical protection with intelligent vector control. Delft Imaging’s ultra-portable digital X-ray devices are enabling TB screening in remote and fragile settings, while Siemens Healthineers is helping deploy cutting-edge AI software to support TB triage and diagnosis.  But they must be deployed widely and equitably to reach those who need them most. That is precisely what the Global Fund enables: equitable access to cutting-edge solutions, delivered through community-led systems that reach those most often left behind. A defining moment for EU Leadership The EU has a unique chance to turn this crisis into an opportunity. The upcoming G20 summit and the Global Fund’s replenishment are pivotal moments.  President Ursula von der Leyen and Commissioner Síkela can send a clear, unequivocal signal: Europe will not stop at “almost”. It will lead until the world is free of AIDS, tuberculosis and malaria.  The Global Fund is a unique partnership that combines financial resources with technical expertise, community engagement and inclusive governance. It reaches those often left behind — those criminalized, marginalized or excluded from health systems.  > Even in Ukraine, amid the devastation of war, the Global Fund partnership has > ensured continuity of HIV and TB services — proof that smart investments > deliver impact, even in crisis. Its model of country ownership and transparency aligns with Africa’s agenda for health sovereignty and with the EU’s commitment to equity and human rights. Even in Ukraine, amid the devastation of war, the Global Fund partnership has ensured continuity of HIV and TB services — proof that smart investments deliver impact, even in crisis. The cost of inaction Some may point to constraints in the Multiannual Financial Framework. But history shows that the EU has consistently stepped up, even in difficult fiscal times. The instruments exist. What’s needed now is leadership to use them. Failure to act would unravel decades of progress. Resurgent epidemics would claim lives, destabilize economies and undermine global health security. The cost of inaction far exceeds the price of investment. For the EU, the risks are strategic as well as moral. Stepping back now would erode the EU’s credibility as champion of human rights and global responsibility. It would send the wrong message, at precisely the wrong time.  Ukraine demonstrates what is at stake: with Global Fund support, millions continue to receive HIV and TB services despite war. Cutting funding now would risk lives not only in Africa and Asia, but also in Europe’s own neighborhood. A call to action Ultimately, this isn’t a question of affordability, but one of foresight. Can the EU afford for the Global Fund not to be fully financed? The answer, for us, is a resounding no. We therefore urge the European Commission to announce a bold, multi-year financial commitment to the Global Fund at the G20.  This pledge would reaffirm the EU’s values and inspire other Team Europe partners to follow suit. It would also support ongoing reforms to further enhance the Global Fund’s efficiency, transparency and inclusivity. > Ultimately, this isn’t a question of affordability, but one of foresight. Can > the EU afford for the Global Fund not to be fully financed? The answer, for > us, is a resounding no. This is more than a funding decision. It is a moment to define the kind of world we choose to build: one where preventable diseases no longer claim lives, where health equity is a reality and where solidarity triumphs over short-termism. Now is the time to reaffirm Europe’s leadership. To prove that when it comes to global health, we will never stop until the fight is won.

France’s constitutional court on Thursday rejected the reintroduction of a controversial insecticide in a significant blow to the government and major farming lobbies that had supported its return. The court’s judges ruled that allowing the use of acetamiprid, an insecticide currently banned in France, would violate the “Charter of the Environment,” a French constitutional text. Acetamiprid’s proposed reintroduction was part of a new French law aiming to make life easier for farmers by allowing the use of some pesticides as well as by cutting red tape and easing permit approval for new breeding and water storage facilities. The judges stressed that neonicotinoids — a class of insecticide that includes acetamiprid and that works by obstructing the nervous systems of insects — can be allowed in exceptional situations but only for a limited time and for well-defined crops. These conditions were not respected in the text of the law, the judges found. The law, which was dubbed “Loi Duplomb” after the conservative senator who introduced it, was a response to the massive farmer protests of 2024. It had already been approved in the parliament. The law is backed by the government and by major farming lobbies but is strongly opposed by left-wing parties, which have flagged its negative impact on biodiversity. More than 2 million French citizens signed a petition launched last month by a 23-year-old student to repeal the law, putting additional pressure on the government. The law polarized French public opinion between the country’s powerful farming lobbies and its more ecologically minded citizens worried about the harm done by pesticides to pollinators and human health. Its opponents urged French President Emmanuel Macron not to sign the law into effect. Macron’s office said Thursday that the president had “taken note” of the ruling and will enact the Duplomb law “as soon as possible” in its modified version per the constitutional court’s ruling. Acetamiprid, in other words, will remain banned. Left-wing opposition figures celebrated the news, with the agriculture ministry expected to comment on the decision later Thursday evening. Farming lobby FNSEA, however, slammed the ruling. “This decision marks the pure and simple abandonment of certain sectors of French agriculture, at a time when our dependence on imports is increasing to the detriment of our social and environmental requirements,” FNSEA President Arnaud Rousseau wrote in a social media post.

PARIS — A petition launched by a 23-year-old student to repeal a new French law on farming has garnered more than 549,000 signatures and could therefore be debated in the French parliament — a first in France’s recent history. The French parliament earlier this month adopted a law, dubbed “Loi Duplomb” after the name of one of its proponents, which its supporters say would make life easier for farmers by cutting red tape, but also by temporarily allowing the use of acetamiprid, an insecticide that has been banned in France since 2018. The text is backed by the government and also by major farmer lobbies FNSEA and Jeunes Agriculteurs, while one left-wing farmers union as well as green and left-wing parties oppose it. The petition launched by Eleonore Pattery — an unknown university student from Bordeaux with a focus on environmental rules — calls for repealing the text, arguing that it is “a scientific, ethical, environmental and health aberration.” On Saturday the number of signatures passed the threshold of 500,000. Beyond that threshold, the heads of parliamentary groups or parliamentary committees can propose to organize a parliamentary debate on it. The president of the National Assembly economic affairs committee, Aurélie Trouvé, from the left-wing France Unbowed party, said she will make that proposal in the fall. “It is the first time it happens in the history of the National Assembly,” a jubilant Trouvé told POLITICO over the phone on Saturday. But, for the debate to happen, the proposal has to first get the nod of the National Assembly’s Conference of Presidents, an organ which gathers key lawmakers including the leaders of permanent parliamentary committees like Trouvé. The Conference of Presidents will meet again on Sept. 12. “I hope that we will be able to have this debate,” Trouvé said, warning that ignoring the petition would be a “democratic denial.” While the text can’t be repealed during the parliamentary debate, the success of the petition is a blow for the government and for farmers’ lobbies that have defended the measure on a symbolical level. France’s Constitutional Council is also looking into the text and could censor part of it if the council considers them to be contrary to the constitution.